Terms: = Bone cancer AND PSA AND Diagnosis
420 results:
1. [Role of bone Scan Index (BSI) in the Prognosis and Treatment Efficacy in Castration-Sensitive Prostate cancer Patients with bone Metastasis].
Deguchi K; Sasaki T; Oue H; Okamoto T; Kato M; Kajiwara S; Higashi S; Masui S; Nishikawa K; Inoue T
Hinyokika Kiyo; 2024 Feb; 70(2):29-37. PubMed ID: 38447942
[TBL] [Abstract] [Full Text] [Related]
2. Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.
Uehara R; Obinata D; Hashimoto S; Nakahara K; Uchida H; Yoshizawa T; Mochida J; Yamaguchi K; Sakaguchi M; Ozawa Y; Mori F; Miura K; Ishige T; Masuda S; Nakayama T; Takahashi S
Medicine (Baltimore); 2024 Mar; 103(9):e37371. PubMed ID: 38428891
[TBL] [Abstract] [Full Text] [Related]
3. Pretreatment level of serum sialic acid predicts both qualitative and quantitative bone metastases of prostate cancer.
Sun J; Tian T; Wang N; Jing X; Qiu L; Cui H; Liu Z; Liu J; Yan L; Li D
Front Endocrinol (Lausanne); 2024; 15():1338420. PubMed ID: 38384968
[TBL] [Abstract] [Full Text] [Related]
4. Analysis of Factors Influencing bone Metastasis in Prostate cancer and Diagnostic Value of Serum psa, CysC and D-D.
Liu X; Zhao C; Lin J; Liu B
Arch Esp Urol; 2024 Jan; 77(1):72-78. PubMed ID: 38374016
[TBL] [Abstract] [Full Text] [Related]
5. Ductal prostate cancer staging: Role of PSMA PET/CT.
Pepe P; Pepe L; Curduman M; Pennisi M; Fraggetta F
Arch Ital Urol Androl; 2024 Feb; 96(1):12132. PubMed ID: 38363231
[TBL] [Abstract] [Full Text] [Related]
6. Nomogram for predicting the overall survival and cancer-specific survival of patients with intraductal carcinoma of the prostate.
Cui Y; Lin J; Sun D; Zhang H; Diao T; Fu Q
J Cancer Res Clin Oncol; 2024 Jan; 150(2):45. PubMed ID: 38281261
[TBL] [Abstract] [Full Text] [Related]
7. Aberrant expression of GATA3 in metastatic adenocarcinoma of the prostate: an important pitfall.
Lobo J; Tenace NP; Cañete-Portillo S; Carneiro I; Henrique R; Lucianò R; Harik LR; Magi-Galluzzi C
Histopathology; 2024 Feb; 84(3):507-514. PubMed ID: 37965687
[TBL] [Abstract] [Full Text] [Related]
8. Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial diagnosis of Patients with Prostate cancer in the United States.
Yee CW; Harvey MJ; Xin Y; Kirson NY
Pharmacoeconomics; 2024 Feb; 42(2):231-247. PubMed ID: 37934376
[TBL] [Abstract] [Full Text] [Related]
9. Diagnostic Performance of PSMA-Based 18 F-DCFPyL PET/CT in Prostate cancer Patients After Definitive Treatment With psa Level ≤0.2 ng/mL.
Lu Y; Wilson ZJ; Xu G; Xu Z; Pan T; Wei P
Clin Nucl Med; 2023 Dec; 48(12):1021-1027. PubMed ID: 37801580
[TBL] [Abstract] [Full Text] [Related]
10. TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate cancer: A Real-World, Multicenter, Retrospective Analysis.
Pisano C; Turco F; Arnaudo E; Fea E; Vanella P; Ruatta F; Filippi R; Brusa F; Prati V; Vana F; Mennitto A; Cattrini C; Vignani F; Dionisio R; Icardi M; Guglielmini P; Buosi R; Stevani I; Vormola R; Numico G; Depetris I; Comandone A; Gennari A; Airoldi M; Rossi M; Vellani G; Ortega C; Tucci M; Maio MD; Buttigliero C
Clin Genitourin Cancer; 2024 Apr; 22(2):56-67.e16. PubMed ID: 37798164
[TBL] [Abstract] [Full Text] [Related]
11. [A Case of Prostate cancer Diagnosed by the bone Biopsy of the Right Iliac Metastatic Lesion].
Konishi M; Okamoto S; Yamamoto T; Kanaki T; Oshima J; Kinjo T; Nakata W; Ohashi H; Inoue H
Hinyokika Kiyo; 2023 Jul; 69(7):193-197. PubMed ID: 37558641
[TBL] [Abstract] [Full Text] [Related]
12. Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapy.
Wenzel M; Garcia CC; Hoeh B; Jorias C; Humke C; Koll F; Tselis N; Rödel C; Graefen M; Tilki D; Chun FKH; Mandel P
Prostate; 2023 Oct; 83(14):1365-1372. PubMed ID: 37464963
[TBL] [Abstract] [Full Text] [Related]
13. Comparing the role of 99m Tc-HYNIC-PSMA-11 and 99m Tc-MDP scintigraphy for the initial staging of intermediate to high-risk prostate cancer.
Ghaedian T; Abdinejad M; Nasrollahi H; Ghaedian M; Firuzyar T
Nucl Med Commun; 2023 Oct; 44(10):864-869. PubMed ID: 37464793
[TBL] [Abstract] [Full Text] [Related]
14. Tumour sink effect on 68Ga-PMSA PET/CT: A case of diffuse metastatic disease of prostate cancer.
Usmani S; Riyami KA; Abubakar S; Jain A; Busaidi AA
J Pak Med Assoc; 2023 Jun; 73(6):1344-1345. PubMed ID: 37427650
[TBL] [Abstract] [Full Text] [Related]
15. Targeted Biopsy in Men High Risk for Prostate cancer:
Pepe P; Pennisi M
Clin Genitourin Cancer; 2023 Dec; 21(6):639-642. PubMed ID: 37394379
[TBL] [Abstract] [Full Text] [Related]
16. Application of machine learning algorithm in prediction of lymph node metastasis in patients with intermediate and high-risk prostate cancer.
Wang X; Zhang X; Li H; Zhang M; Liu Y; Li X
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8759-8768. PubMed ID: 37127828
[TBL] [Abstract] [Full Text] [Related]
17.
Pepe P; Pepe L; Tamburo M; Marletta G; Savoca F; Pennisi M; Fraggetta F
In Vivo; 2023; 37(3):1318-1322. PubMed ID: 37103095
[TBL] [Abstract] [Full Text] [Related]
18. Metastasis of primary signet ring cell carcinoma of prostate to bone marrow: A rare occurrence with review of literature.
Jamal I; Raman RB; Kumar S; Agrawal R; Choudhary VN
Indian J Pathol Microbiol; 2023; 66(2):407-410. PubMed ID: 37077098
[TBL] [Abstract] [Full Text] [Related]
19. Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation.
Sureka SK; Misra A; Raj H; Shukla A; Singh UP
Int Urol Nephrol; 2023 May; 55(5):1133-1137. PubMed ID: 36917412
[TBL] [Abstract] [Full Text] [Related]
20. Risk Evaluation of bone Metastases and a Simple Tool for Detecting bone Metastases in Prostate cancer: A Population-Based Study.
Li S; Chen C; Zhu H; Lin Q; Yu Z
Comput Math Methods Med; 2023; 2023():9161763. PubMed ID: 36824150
[TBL] [Abstract] [Full Text] [Related]
[Next]
